Oramed sells Oratech subsidiary to Lifeward for 50% equity stake, invests $9M in convertible notes

Filed March 31, 2026 · Period ending March 25, 2026 · ~1 min read

Key Changes

• high

  Oramed divested wholly-owned subsidiary Oratech to Lifeward for ~50% equity stake (1.25M shares, 1M pre-funded warrants at $0.0001, and 1.3M warrants at $5.40), transforming from subsidiary owner to major Lifeward shareholder

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  Simultaneously invested $9M in Lifeward senior secured convertible notes (convertible at $5.40/share) plus warrants for 1.67M additional shares at $5.40, becoming both major shareholder and creditor

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• medium

  Secured 4% revenue share on Lifeward's ReWalk exoskeleton product sales for up to 10 years, terminating earlier if maximum amount reached or Lifeward market cap hits $200M

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →